Dystrophin restoration in skeletal, heart and skin arrector pili smooth muscle of mdx mice by ZM2 NP-AON complexes

Gene Therapy

Volumn 17, Issue 3, 2010, Pages 432-438

  Ferlini, A ^a   Sabatelli, P ^a,b   Fabris, M ^a   Bassi, E ^a   Falzarano, S ^a   Vattemi, G ^c   Perrone, D ^a   Gualandi, F ^a   Maraldi, N M ^d   Merlini, L ^a   Sparnacci, K ^e   Laus, M ^e   Caputo, A ^f   Bonaldo, P ^f   Braghetta, P ^f   Rimessi, P ^a  

^a UNIVERSITY OF FERRARA   (Italy)

^b CNR   (Italy)

^c UNIVERSITY OF VERONA   (Italy)

^d UNIVERSITY OF BOLOGNA   (Italy)

^e UNIVERSITY OF EASTERN PIEDMONT   (Italy)

^f UNIVERSITY OF PADOVA   (Italy)

Author keywords

Antisense; Arrector pili; Dystrophin; Nanoparticles; Smooth muscle

Indexed keywords

ALPHA SARCOGLYCAN; ANTISENSE OLIGONUCLEOTIDE; BETA SARCOGLYCAN; BIOLOGICAL MARKER; DELTA SARCOGLYCAN; DYSTROPHIN; GAMMA SARCOGLYCAN; NANOPARTICLE; POLY(METHYL METHACRYLATE); POLY(N ISOPROPYLACRYLAMIDE);

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARRECTOR PILI MUSCLE; ARTICLE; ASSAY; CONTROLLED STUDY; DRUG MONITORING; EXON; HEART MUSCLE; MOUSE; MUSCLE CELL; NONHUMAN; PRIORITY JOURNAL; PROTEIN LOCALIZATION; PROTEIN SYNTHESIS; REVERSE TRANSCRIPTION POLYMERASE CHAIN REACTION; SKELETAL MUSCLE; SKIN APPENDAGE; SMOOTH MUSCLE; SMOOTH MUSCLE FIBER; WESTERN BLOTTING; X CHROMOSOME LINKED MUSCULAR DYSTROPHIC MOUSE;

ACRYLAMIDES; ANIMALS; DYSTROPHIN; EXONS; GENE THERAPY; HEART; HUMANS; MALE; MICE; MICE, INBRED MDX; MUSCLE, SMOOTH; MUSCULAR DYSTROPHY, DUCHENNE; NANOPARTICLES; OLIGORIBONUCLEOTIDES, ANTISENSE; POLYMETHYL METHACRYLATE; SARCOGLYCANS; SKIN;

ANIMALIA; MUS;

EID: 77949423798     PISSN: 09697128     EISSN: 14765462     Source Type: Journal    
DOI: 10.1038/gt.2009.145     Document Type: Article

References (19)

1. Aartsma-Rus A, Van Deutekom JC, Fokkema IF, Van Ommen GJ, Den Dunnen JT. Entries in the Leiden Duchenne muscular dystrophy mutation database: an overview of mutation types and paradoxical cases that confirm the reading-frame rule. Muscle Nerve 2006; 34: 135-144.
2. Hamed SA. Drug evaluation: PTC-124\a potential treatment of cystic fibrosis and Duchenne muscular dystrophy. IDrugs 2006; 9: 783-789.
3. Aartsma-Rus A, van Ommen GJ. Antisense-mediated exon skipping: a versatile tool with therapeutic and research applications. RNA 2007; 13: 1609-1624 (Review).
4. Hoffman E. Skipping toward personalized molecular medicine. N Engl J Med 2007; 357: 2719-2722.
5. Du L, Gatti R. Progress toward therapy with antisense-mediated splicing modulation. Curr Opin Mol Ther 2009; 11: 116-123.
6. van Deutekom J, Janson AA, Ginjaar IB, Frankhuizen WS, Aartsma-Rus A, Bremmer-Bout M et al. Local dystrophin restoration with antisense oligonucleotide PRO 051. N Engl J Med 2007; 357: 2677-2686.
7. Lu Q, Rabinowitz A, Chen YC, Yokota T, Yin H, Alter J et al. Systemic delivery of antisense oligoribonucleotide restores dystrophin expression in body-wide skeletal muscles. Proc Natl Acad Sci USA 2005; 102: 198-203.
8. Alter J, Lou F, Rabinowitz A, Yin H, Rosenfeld J, Wilton SD et al. Systemic delivery of morpholino oligonucleotide restores dys-trophin expression bodywide and improves dystrophic pathology. Nat Med 2006; 12: 175-177.
9. Heemskerk H, de Winter CL, de Kimpe SJ, van Kuik-Romeijn P, Heuvelmans N, Platenburg GJ et al. In vivo comparison of 2-O-methyl phosphorothioate and morpholino antisense oligonu-cleotides for duchenne muscular dystrophy exon skipping. J Gene Med 2009; 11: 257-266.
10. Popplewell L, Trollet C, Dickson G, Graham IR. Design of phosphorodiamidate morpholino oligomers (PMOs) for the induction of exon skipping of the human DMD gene. Mol Ther 2009; 17: 554-561.
11. Rimessi P, Sabatelli P, Fabris M, Braghetta P, Bassi E, Spitali P et al. Cationic PMMA nanoparticles bind and deliver antisense oligoribonucleotides allowing restoration of dystrophin expression in the mdx mouse. Mol Ther 2009; 17: 820-827.
12. Malerba A, Thorogood FC, Dickson G, Graham IR. Dosing regimen has a significant impact on the efficiency)of morpho-lino oligomer-induced exon skipping in mdx mice. Hum Gene Ther 2009; 20: 955-965.
13. Marbini A, Gemignani F, Bellanova MF, Guidetti D, Ferrari A. Immunohistochemical localization of utrophin and other cytos-keletal proteins in skin smooth muscle in neuromuscular diseases. J Neurol Sci 1996; 143: 156-160.
14. Marbini A, Marcello N, Bellanova MF, Guidetti D, Ferrari A, Gemignani F. Dystrophin expression in skin biopsy immuno-histochemical. Localisation of striated muscle type dystrophin. J Neurol Sci 1995; 129: 29-33.
15. Tanveer N, Sharma MC, Sarkar C, Gulati S, Kalra V, Singh S et al. Diagnostic utility of skin biopsy in dystrophinopathies. Clin Neurol Neurosurg 2009; 111: 496-502.
16. Gleason R, Dye WW, Wilson E, Humphrey JD. Quantification of the mechanical behavior of carotid arteries from wild-type, dystrophin-deficient, and sarcoglycan-delta knockout mice. J Biomech 2008; 41: 3213-3218.
17. Prentice R. Surrogate and mediating endpoints: current status and future directions. J Natl Cancer Inst 2009; 101: 216-217.
18. Mandrekar S, Sargent DJ. Clinical trial designs for predictive biomarker validation: one size does not fit all. J Biopharm Stat 2009; 19: 530-542.
19. McShane L, Hunsberger S, Adjei AA. Effective incorporation of biomarkers into phase II trials. Clin Cancer Res 2009; 15: 1898-1905.